AB0478 PREGNANCY OUTCOME IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH HYDROXYCHLOROQUINE: 10 YEARS EXPERIENCE

Abstract

Background: Pregnancy in SLE patients is closely associated with the usage of hydroxychloroquine [1]. Objectives: To determine pregnancy outcomes in women with Systemic Lupus Erythematosus who were treated with hydroxychloroquine in Universiti Kebangsaan Malaysia Medical Centre. Methods: Pregnant women with Systemic Lupus Erythematosus who had antenatal follow up and delivery in Universiti Kebangsaan Malaysia Medical Centre between 1stJanuary 2007 and 1st January 2017 were retrospectively analyzed. Data collection was done via medical case notes and laboratory investigations. Study population was categorised into two groups based on hydroxychloroquine treatment during pregnancy. Incomplete pregnancy records were excluded. Results: There were 82 completed pregnancies included with 47 (57.3%) in HCQ group and 35 (42.7%) in non HCQ group. Amongst HCQ users, there were significantly more pregnancies with musculoskeletal involvement (p=0.03), heavier mean neonatal birth weight (p=0.02) and prolonged duration of pregnancy (p=0.001). In non-HCQ users, the rate of recurrent miscarriages (p=0.003), incidence of hypertension (p=0.01) and gestational diabetes mellitus (p=0.01) and concurrent medical illness (p=0.005) were significantly more. Hydroxychloroquine use during pregnancy was protective against hypertension (p=0.001) and the gestational age at delivery had significant effect on the neonatal birth weight (p=0.001). However, duration of the disease had significant negative effect on the neonatal birth weight (p=0.016). Conclusion: HCQ enhance better neonatal outcomes and reduce adverse pregnancy outcome and antenatal complications such as hypertension and diabetes.